Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats

Kidney and Blood Pressure Research

Volumn 30, Issue 4, 2007, Pages 212-223

  Choi, Bum Soon ^b   Yang, Hyun Ju ^b   Ahn, Kyung Ohk ^b   Lim, Sun Woo ^b   Kim, Su Hyun ^b   Kim, Jin Young ^b   Li, Can ^b   Kim, Yong Soo ^b   Kim, Jin ^b   Bang, Byung Kee ^b   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b NONE

Author keywords

Nephropathy, hypertensive; Peroxisome proliferator activator agonist; Renal protection

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; OSTEOPONTIN; PROFIBROTIC CYTOKINE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HISTOPATHOLOGY; HYPERTENSIVE NEPHROPATHY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MALE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; STATISTICAL SIGNIFICANCE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THIAZOLIDINEDIONES;

EID: 34447532231     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104090     Document Type: Article

References (50)

1. Brunner HR, Laragh JH, Baer L, Vaughan ED Jr: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-449.
2. Sadoshima S, Kurozumi T, Tanaka K, Ueda K, Takeshita M, Hirota Y, Omae T, Uzawa H, Katsuki S: Cerebral and aortic atherosclerosis in Hisayama, Japan. Atherosclerosis 1980;36:117-126.
3. Raij L: Role of hypertension in progressive glomerular injury in glomerulonephritis. Hypertension 1986;8:130-133.
4. Johnson DB, Dell'Italia LJ: Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertens 1996;5:186-191.
5. Inada Y, Tazawa S, Murakami M, Akahane M: KRH-594, a new angiotensin AT1 receptor antagonist, prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats. Clin Exp Pharmacol Physiol 2001;28:206-211.
6. Luke RG: Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of endstage renal disease. Nephrol Dial Transplant 1999;14:2271-2278.
7. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
8. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879-887.
9. Itoh H: PPARs and hypertension. Nippon Rinsho 2005;63:631-642.
10. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
11. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
12. Wang H, Delaney KH, Kwiecien JM, Smeda JS, Lee RMKW: Prevention of stroke with perindopril treatment in stroke-prone spontaneously hypertensive rats. Clin Invest Med 1997;20:327-338.
13. Chung BH, Lim SW, Ahn KO, Sugawara A, Ito S, Choi BS, Kim YS, Bang BK, Yang CW: Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 2005;10(suppl 1):S40-S43.
14. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU: Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003;52:2331-2337.
15. Wu L, Wang R, De Champlain J, Wilson TW: Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 2004;17:749-756.
16. Wakino S, Hayashi K: Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway. Nippon Rinsho 2005;63:693-699.
17. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-2302.
18. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN: Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension. Hypertension 2003;42:664-668.
19. Sarafidis PA, Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pagkalos EM, Yovos JG, Pliakos CI, Tourkantonis AA: The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005;18:227-234.
20. Sarafidis PA, Lasaridis AN, Nilsson PM, Pagkalos EM, Hitoglou-Makedou AD, Pliakos CI, Kazakos KA, Yovos JG, Zebekakis PE, Tziolas IM, Tourkantonis AN: Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004;22:1769-1777.
21. Zoja C, Benigni A, Remuzzi G: Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 2004;13:31-37.
22. Bagchus WM, Jeunink MF, Elema JD: The mesangium in anti-thy-1 nephritis: influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation. Am J Pathol 1990;137:215-223.
23. van Goor H, Fidler V, Weening JJ, Grond J: Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: evidence for involvement of macrophages and lipids. Lab Invest 1991;64:754-765.
24. van Goor H, van der Horst ML, Fidler V, Grond J: Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 1992;66:564-571.
25. Nathan CF: Secretory products of macrophages. J Clin Invest 1987;79:319-326.
26. Chung BH, Li C, Sun BK, Lim SW, Ahn KO, Yang JH, Choi YH, Yoon KH, Sugawara A, Ito S, Kim J, Yang CW: Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005;5:1856-1867.
27. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998;52:353-358.
28. O'Regan A, Berman JS: Osteopontin: a key cytokine in cell mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-390.
29. Border WA, Noble NA, Ketteler M: TGF-β: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int 1995;47:S59-S61.
30. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor. Nature 1990;346:371-374.
31. O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, Kimura T, Nobuyoshi M, Mizgala H, Purchio A, Schwart SM: Beta ig-h3, a transforming growth factor-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol 1996;16:576-584.
32. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M: Peroxisome proliferatoractivated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:2002-2008.
33. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59:1899-1910.
34. Collison M, Glazier AM, Graham D, Morton JJ, Dominiczak MH, Aitman TJ, Connell JM, Gould GW, Dominiczak AF: Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes 2000;49:2222-2226.
35. Bedir A, Aliyazicioglu Y, Kahraman H, Yurdakul Z, Uysal M, Suvaci DE, Okuyucu A, Hokelek M, Alvur M: Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone. Environ Mol Mutagen 2006;47:718-724.
36. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003;108:2805-2811.
37. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003;23:267-276.
38. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM: Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 2005;54:554-562.
39. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL: Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 2004;62:135-144.
40. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004;286:H742-H748.
41. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003;108:2805-2811.
42. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003;107:2548-2550.
43. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:930-934.
44. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004;286:H742-H748.
45. Shigenaga MK, Gimeno CJ, Ames BN: Urinary 8-hydroxy-2′- deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 1989;86:9697-9701.
46. Harrison DG: From isolated vessels to the catheterization laboratory: studies of endothelial function in the coronary circulation of humans. Circulation 1989;80:703-706.
47. Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA: Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett 1999;110:119-127.
48. Fujiwara T, Yuasa H, Ogiku N, Kawai Y: Histopathological investigation on salt-loaded stroke-prone spontaneously hypertensive rats, whose biochemical parameters of renal dysfunction were ameliorated by administration of imidapril. Jpn J Pharmacol 1994;66:231-240.
49. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effects. Am J Hypertens 1991;4:680-687.
50. Miyagishi A, Maniwa T, Noguchi T, Hara Y: Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. Clin Exp Hypertens 1991;13:1077-1089.